Real-time index price for S&P 500 Financials [Sector] (SRFI), along with buy or sell indicators, analysis, charts, historical performance, news and more ...

Wall St. Insights The seemingly endless political season is almost over. It’s possible we won’t know the winner for a while.

JMP Securities initiates coverage on Summit Therapeutics, citing promising data for ivonescimab in NSCLC and setting a $32 ...

Bristol-Myers Squibb (BMY) stock gained as the comany exceeded Q3 2024 financial forecasts, with strong revenue growth and ...

Growth portfolio primarily comprises sales from immuno-oncology drugs like Opdivo, Orencia, Yervoy, Reblozyl, Opdualag, ...

It nudges the body’s inherent defence mechanism to take on the invading cells. That is the reason why Keytruda and other drugs like Opdivo (nivolumab) of Bristol Myers Squibb are categorised as ...

The firm sees growth headwinds from the Eliquis and Opdivo loss of exclusivities. Bristol is in a transition period from 2025 through 2027, which will likely add volatility, the analyst tells ...

Fortune 500 ranks top 500 U.S. companies by revenue, spotlighting reliable investment targets. Fortune Global 500 lists top 500 global firms, helping diversify investment portfolios. To join ...

Checkpoint inhibitors, a class of drugs that includes the widely used Keytruda and Opdivo, represent a substantial portion of the cancer treatment market. However, the ODAC's findings suggest that ...

All are rated Buy at top Wall Street firms. Since 1926, dividends have contributed approximately 32% of the total return for the S&P 500, while capital appreciations have contributed 68%.